|
lamf@uthscsa.edu |
Research InterestDr. Lam's research focus is pharmacokinetic, pharmacodynamic, and pharmacogenetic aspect of drug therapy. Specifically, he is interested in how inter-individual variability in drug metabolism can affect response to drugs and susceptibility to biological disorder. The overall goal of his research activities is the application and integration of the three disciplines in different therapeutic areas, primarily neuropsychopharmacology, drug abuse, and oncology. Over the years, the research has evolved from animal and clinical evaluations of psychotropics such as haloperidol and clozapine, to more recent investigations in which probe markers were used to study significance and implications of change in metabolic enzyme activity induced by psychoactive drugs. Drug metabolism and response remain a common theme of these research activities. |
Lam YWF, Arana CJ, Shikuma LR, Rotschafer JC. The clinical utility of a published nomogram to predict aminoglycoside nephrotoxicity. JAMA 1986;255:639-42.
Chang WH, Lin SK, Jann MW, Lam YWF, Chen TY, Chen CT, Hu WH, Yeh EK. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biol Psychiatry 1989;26:239-49.
Jann MW, Lam YWF, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacology 1990;101:107-11.
Lam YWF, Boyd RA, Chin SK, Chang D, Giacomini KM. Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. J Clin Pharmacol 1991;31:429-32.
Lam YWF, Chang WH, Jann MW, Chen H. Variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. Neuropsychopharmacology 1992,7:33-9.
Lam YWF, Jann MW, Chang WH, Yu HS, Lin SK, Chen H, Davis CM. Polymorphism in reduced haloperidol to haloperidol ratios in different ethnic groups. J Clin Pharmacol 1995;35:128-36.
Jann MW, Lam YWF, Chang WH. Rapid formation of clozapine in guinea pigs and man following clozapine N oxide administration. Arch Int Pharmacodyn 1994;328:243-50.
Alfaro C, Lam YWF, Ereshefsky L, Simpson J. CYP2D6 status of extensive metabolizers follwoing multiple dose administration of fluvoxamine, fluoxetine, sertraline, or paroxetine. J Clin Psychopharmacol 1999;19:155-63.
Alfaro C, Lam YWF, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. J Clin Pharmacology 2000;40:58-66.
Lam YWF, Ereshefsky, LE, Toney GB, Gonzales C. Branded versus generic clozapine: Bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001;62(Suppl 5):18-22.
"P-450 Enzymes, Drug Interactions, and Cancer Chemotherapy ". National Cancer Institute Pediatric Oncology Group Annual Spring Meeting, St. Petersberg Beach, Florida. April 1998.
"The Clinical Relevance of Cytochrome P-450 Enzymes". National Institute of Mental Health New Clinical Drug Evaluation Unit (NCDEU) Program 38th Annual Meeting, Boca Raton, Florida. June 1998.
"Pharmacokientic and Pharmacodynamic Consequences of Reboxetine and Nefazodone Interaction With Alprazolam". VII World Conference on Clinical Pharmacology and Therapeutics, Florence, Italy. July, 2000.
"Genetic Polymorphisms and Clinical Psychiatry", Translational Research Symposium on Pharmacogenetics: More than Drug Metabolism. American College of Clinical Pharmacy Annual Meeting, Los Angeles, California. November 2000.
"Herbal Products as Psychotherapeutic Agents: The Opportunities and the Challenges". Institute of Mental Health Research and Department of Psychiatry, University of Ottawa, Ottawa, Canada. April, 2001.
UT Home Page | Pharmacy Home Page | Pharmacotherapy Home Page